argenx SE reported $472M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
AstraZeneca USD 2.51B 573M Jun/2026
Genmab DKK 31M 370M Dec/2025
GlaxoSmithKline GBP 435M 1.3B Jun/2026
GRIFOLS EUR 154M 81M Jun/2026
Hikma Pharmaceutical USD 164M 45M Dec/2025
Lakefront Biotherapeutics EUR 14.49M 767.65M Mar/2026
Qiagen NV USD 68.04M 39.79M Mar/2026
UCB EUR 1.08B 608M Dec/2025